Haplotype-based non-invasive prenatal diagnosis of recessive dystrophic epidermolysis bullosa via targeted capture sequencing of maternal plasma

J Dermatol. 2023 Jul;50(7):946-950. doi: 10.1111/1346-8138.16760. Epub 2023 Mar 7.

Abstract

Recessive dystrophic epidermolysis bullosa (RDEB) is a rare and severe hereditary skin disease, caused by mutations in the COL7A1. However, whether non-invasive prenatal testing (NIPT) can be used for this monogenic genodermatosis remains unknown. Accordingly, we conducted a study in which one couple at high risk of having a fetus with RDEB were recruited and tested by haplotyping-based NIPT. Next-generation sequencing-based multi-gene panel testing was carried out in this couple and their first child as proband who was affected with RDEB. We deduced parental haplotypes via single nucleotide polymorphism (SNP)-based haplotype linkage analysis. Then the maternal plasma cell-free DNA was also sequenced to determine the fetal haplotypes using a parental haplotype-assisted hidden Markov model (HMM) analysis. Results show that the fetus was only a heterozygous mutation carrier in COL7A1 and the identical results were obtained after birth. These results demonstrate that haplotyping-based NIPT is a feasible method for NIPT of RDEB.

Keywords: COL7A1; SNP haplotyping; next generation sequencing; non-invasive prenatal testing; recessive dystrophic epidermolysis bullosa.

MeSH terms

  • Child
  • Collagen / genetics
  • Collagen Type VII / genetics
  • Epidermolysis Bullosa Dystrophica* / diagnosis
  • Epidermolysis Bullosa Dystrophica* / genetics
  • Female
  • Genes, Recessive
  • Haplotypes
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Mutation
  • Pregnancy
  • Prenatal Diagnosis

Substances

  • Collagen
  • Collagen Type VII
  • COL7A1 protein, human